pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,179 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1177Endpoints893BioPharma Dive344BioSpace310Fierce Biotech290onclive165raps106globenewswire health73
therapy area
allOncology7622Rare Disease1876Cardiology1743Immunology1482Hematology1323Vaccines1197Pulmonology
  • Study Finds Screening Gap for HTLV-1 Linked Leukemia in US Caribbean-Born Communities
    Researchers at Sylvester Comprehensive Cancer Center have highlighted a gap in screening for adult T‑cell leukemia/lymphoma (ATLL) that could be addressed by preventing mother‑to‑child transmission…
    onclive · 4mo agoPositive↗ source
  • Study finds researchers become less disruptive as they age, favoring incremental work
    A new study published in Science reports that scientists tend to produce their most disruptive work early in their careers, but shift toward less groundbreaking research as they get older. The ana…
    STAT · 4mo agoNeutral↗ source
← prev
page 114 of 128
next →
fda recalls70
fda medwatch60
fda press38
1189
Psychiatry & CNS866
Ophthalmology496
Pain480
Endocrinology & Metabolism474
Infectious Disease444
CDC’s cruise ship health chief Luis Rodríguez retires amid hantavirus outbreak on MV Hondius
The Centers for Disease Control and Prevention announced that Luis Rodríguez, who has been with the Vessel Sanitation Program since 2010 and its chief since 2023, will retire. His departure comes…
STAT · 4mo agoNeutral↗ source
  • AAAS elects oncology leaders Guise and Watowich, highlight mentorship for early-career researchers
    Theresa A. Guise, MD, FASBMR, and Stephanie S. Watowich, PhD, have been elected as fellows of the American Association for the Advancement of Science (AAAS). The fellowship recognizes scientists wh…
    onclive · 4mo agoPositive↗ source
  • STAT Health Tech newsletter highlights OpenAI health policy ideas and Dexcom CGM updates
    The latest STAT Health Tech newsletter, edited by Mario Aguilar, offers a roundup of recent technology developments in health care. OpenAI proposes a set of health policy recommendations aimed at…
    STAT · 4mo agoNeutral↗ source
  • Pennsylvania sues AI chatbot company for posing as a licensed doctor
    The state of Pennsylvania has sued Character.AI, a startup that lets users chat with different AI-generated personas, for illegally presenting a chatbot as a licensed doctor in the state. This is t…
    Endpoints · 4mo ago↗ source
  • EGFR-Targeted Therapy Sequencing After Resistance in NSCLC
    Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.
    onclive · 4mo ago↗ source
  • HERIZON-GEA-01 Study Design, Geographic Distribution, and PD-L1 Testing Considerations
    Experts debate PD‑L1 testing in HER2+ metastatic gastric cancer as new trial data reshapes when to add immunotherapy.
    onclive · 4mo ago↗ source
  • Integrating Evidence and Identifying Future Research Needs in Metastatic Castration Sensitive Prostate Cancer (mCSPC)
    Experts debate real-world evidence for prostate cancer drug comparisons, weighing trial limits, bias, and data that guides care.
    onclive · 4mo ago↗ source
  • Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEA
    Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.
    onclive · 4mo ago↗ source
  • Co-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy Response
    Learn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.
    onclive · 4mo ago↗ source
  • Evaluating Observational and Propensity Matched Studies in Metastatic Castration Sensitive Prostate Cancer (mCSPC)
    Experts weigh real‑world evidence for prostate cancer drug comparisons, explaining bias risks, data quality, and how it complements trials.
    onclive · 4mo ago↗ source
  • Reigniting Your Curiosity During Fellowship
    Megan M. Dupuis, MD, PhD, discusses how oncology fellows can keep their personal and professional curiosities alive during fellowship.
    onclive · 4mo ago↗ source
  • STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
    The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
    STAT · 4mo ago↗ source
  • Hospital shootings steadily increased since 2000
    What the FDA has lost, why hantavirus isn't the next pandemic, and more health news from Morning Rounds
    STAT · 4mo ago↗ source
  • STAT+: Next-gen Duchenne drug from Entrada disappoints
    A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.
    STAT · 4mo ago↗ source
  • Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst
    Angelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases. The buyout will add three medicines to Angelini’s po…
    Endpoints · 4mo ago↗ source
  • STAT+: Color me skeptical: Drinking gold is not an ALS cure
    In this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water as an ALS treatment.
    STAT · 4mo ago↗ source
  • STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
    The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.
    STAT · 4mo ago↗ source
  • STAT+: What was lost at the FDA
    What was lost at the FDA: A year after DOGE’s cuts, six agency staffers describe the work they never thought they’d leave.
    STAT · 4mo ago↗ source
  • Opinion: Eugene Braunwald, ‘father of modern cardiology,’ told me he had two dreams. One came true
    Legendary cardiologist Eugene Braunwald had two visions for his career. One of them came true.
    STAT · 4mo ago↗ source
  • Cruise ship hantavirus outbreak worries experts, though they discount pandemic fears
    Scientists are worried that hantaviruses haven’t been as well studied as they ought to be, but not that the MV Hondius cruise ship is ground zero for the next pandemic.
    STAT · 4mo ago↗ source
  • MANEUVER Trial Underscores Potential Paradigm Shift Toward Targeted Approaches in TGCT
    R. Lor Randall, MD, FACS, discusses how the introduction of systemic therapies like pimicotinib in TGCT enables a tumor biology–informed approach to care.
    onclive · 4mo ago↗ source
  • STAT+: Oregon hospitals won’t outsource to national physician chain after all
    Faced with stiff local opposition and a possible loss in court, PeaceHealth drops plan to replace Eugene Emergency Physicians with staffing chain ApolloMD.
    STAT · 4mo ago↗ source
  • Trump administration’s drug strategy is at odds with recent actions on funding, policy
    The White House nods to medication-assisted treatment and fentanyl test strips, despite recently placing new limits.
    STAT · 4mo ago↗ source